Last updated: February 19, 2026
Daratumumab, a human monoclonal antibody targeting CD38, demonstrates continued expansion across multiple myeloma (MM) treatment settings and emerging indications. Clinical trial data indicate sustained efficacy and improved safety profiles, supporting its established market position and projecting continued growth.
What are the Latest Clinical Trial Developments for Daratumumab?
Daratumumab's clinical development is characterized by ongoing trials investigating its efficacy in various stages of multiple myeloma and potential new indications.
Daratumumab in Relapsed/Refractory Multiple Myeloma (RRMM)
Daratumumab, in combination with pomalidomide and dexamethasone (DPd), shows durable responses in patients with RRMM who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor. Data from the POLLUX study (NCT02076009) indicate a progression-free survival (PFS) benefit.
In the SIRIUS study (NCT02314755), daratumumab monotherapy demonstrated significant improvements in overall response rate (ORR) and duration of response (DoR) in patients with RRMM refractory to multiple prior lines of therapy. This data supported its initial approval in this setting.
Daratumumab in Newly Diagnosed Multiple Myeloma (NDMM)
The MAJESTC-R study (NCT02597951) evaluated daratumumab, lenalidomide, bortezomib, and dexamethasone (DRd) as induction therapy followed by daratumumab monotherapy as maintenance in NDMM. Results showed high response rates and extended PFS.
The GRIFFIN study (NCT02858343) is investigating daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) versus RVd alone as induction therapy in NDMM patients eligible for autologous stem cell transplant (ASCT). Early data suggest D-RVd leads to deeper responses, including higher rates of minimal residual disease (MRD) negativity.
Daratumumab in Transplant-Ineligible NDMM
The ALCYONE study (NCT02195132) assessed daratumumab, bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible NDMM patients. D-VMP demonstrated a significant reduction in the risk of disease progression or death.
Daratumumab in Maintenance Therapy
Daratumumab is being evaluated as maintenance therapy post-ASCT and post-induction in transplant-eligible and ineligible patients, respectively. These studies aim to prolong remission duration and improve long-term outcomes. The design of these trials focuses on extending PFS and overall survival (OS).
Daratumumab in Other Hematological Malignancies
Preclinical and early-phase clinical studies are exploring daratumumab's potential in other CD38-expressing hematological malignancies, including:
- Amyloidosis: Investigated in relapsed or refractory AL amyloidosis.
- Mantle Cell Lymphoma (MCL): Early-phase trials are assessing its efficacy.
- Chronic Lymphocytic Leukemia (CLL): CD38 expression is a marker of poor prognosis in CLL, making daratumumab a potential therapeutic option.
What is the Current Market Landscape for Daratumumab?
Daratumumab, marketed as Darzalex and Darzalex Faspro, holds a dominant position in the multiple myeloma market. Its broad labeling across various treatment lines and its combination potential drive significant market share.
Key Market Drivers:
- Expanding Indications: Approval in NDMM upfront and in earlier lines of relapsed/refractory disease expands the addressable patient population.
- Combination Therapies: Daratumumab's efficacy is enhanced when combined with standard-of-care agents (e.g., proteasome inhibitors, IMiDs).
- Subcutaneous Formulation (Darzalex Faspro): The subcutaneous formulation offers improved administration convenience and reduced infusion times, enhancing patient and physician acceptance. This has been crucial for broader adoption and market penetration.
- Long-Term Efficacy Data: Sustained PFS and OS benefits observed in pivotal trials support continued physician confidence and prescription volume.
- Global Market Access: Expanding regulatory approvals and reimbursement in major global markets contribute to its commercial success.
Market Share and Competition:
Daratumumab is a leading therapy in the MM market, competing with other novel agents including other monoclonal antibodies (e.g., isatuximab), CAR T-cell therapies (e.g., idecabtagene vicleucel, ciltacabtagene autoleucel), and bispecific antibodies. However, daratumumab's established safety profile and broad clinical utility position it favorably.
Table 1: Daratumumab Market Positioning by Treatment Line (Multiple Myeloma)
| Treatment Line |
Key Combination Regimens |
Current Status |
| Newly Diagnosed Multiple Myeloma (NDMM) - Transplant Eligible |
D-RVd (Daratumumab, lenalidomide, bortezomib, dexamethasone) |
Growing adoption |
| NDMM - Transplant Ineligible |
D-VMP (Daratumumab, bortezomib, melphalan, prednisone) |
Established standard |
| Relapsed/Refractory Multiple Myeloma (RRMM) - 1st Line |
DRd (Daratumumab, lenalidomide, dexamethasone) |
Established standard |
| RRMM - 2nd Line & Subsequent |
DPd (Daratumumab, pomalidomide, dexamethasone) |
Established standard |
| RRMM - Monotherapy (prior therapies failed) |
Daratumumab |
Established standard |
| Maintenance Therapy |
Post-ASCT or post-induction |
Emerging standard |
Data compiled from clinical trial outcomes and market reports.
Pricing and Reimbursement:
Daratumumab is a high-cost therapy, reflecting the significant R&D investment and clinical value it provides. Pricing strategies vary by region, with ongoing negotiations with payers to ensure market access and affordability. The introduction of the subcutaneous formulation did not significantly alter the overall pricing structure but improved value proposition due to efficiency gains.
What is the Projected Market Growth for Daratumumab?
The market for daratumumab is projected to experience robust growth driven by its expanding clinical utility and the increasing prevalence of multiple myeloma.
Key Growth Drivers:
- Continued Label Expansion: Ongoing clinical trials investigating daratumumab in earlier lines of therapy and in combination with newer agents are expected to yield positive results and further expand its approved indications.
- Real-World Evidence (RWE): Accumulation of RWE demonstrating long-term benefits and favorable safety profiles in diverse patient populations will reinforce its clinical value and drive uptake.
- Geographic Expansion: Increased market penetration in emerging markets will contribute to sales growth.
- Combination with Novel Therapies: Daratumumab's role in combination regimens, including with bispecific antibodies and CAR T-cell therapies, may evolve and drive further utilization.
- Potential New Indications: Positive results in ongoing trials for amyloidosis or other hematological malignancies could open up new revenue streams.
Market Size and Forecast:
The global market for daratumumab is estimated to be in the multi-billion dollar range. Projections indicate a compound annual growth rate (CAGR) in the high single digits to low double digits over the next five to seven years. This growth will be fueled by its increasing use in upfront treatment for NDMM and its established role in relapsed/refractory settings.
Table 2: Projected Daratumumab Market Growth Factors
| Factor |
Impact on Growth |
Timeline |
| NDMM Upfront Treatment Uptake |
Significant positive |
Short to medium |
| RRMM Sequential Use |
Moderate positive |
Medium |
| Subcutaneous Formulation Adoption |
Moderate positive |
Ongoing |
| New Combination Regimen Approvals |
Significant positive |
Medium to long |
| Expansion into Other Indications |
Potential positive |
Long |
| Competitive Landscape Evolution |
Moderate negative |
Ongoing |
Analysis based on market trends and clinical pipeline.
Risks and Challenges:
- Emergence of Potent Competitors: New classes of therapies, particularly CAR T-cell therapies and bispecific antibodies, offer novel mechanisms of action and may challenge daratumumab's market dominance in certain patient segments.
- Pricing Pressure: Increasing scrutiny on drug pricing by healthcare systems and payers could impact profitability.
- Manufacturing and Supply Chain: Ensuring consistent and sufficient supply of a complex biologic is critical.
- Long-Term Safety and Efficacy Monitoring: Continued monitoring for rare adverse events and long-term efficacy is necessary.
- Biosimilar Competition: While biosimilar competition for monoclonal antibodies is a long-term consideration, it is not an immediate threat to daratumumab given its patent exclusivity for the foreseeable future.
Table 3: Competitive Landscape Snapshot (Multiple Myeloma)
| Drug/Therapy Class |
Mechanism of Action |
Key Developers |
Market Stage |
| Daratumumab (Anti-CD38) |
Monoclonal antibody targeting CD38 |
Janssen (J&J) |
Established, expanding |
| Isatuximab (Anti-CD38) |
Monoclonal antibody targeting CD38 |
Sanofi |
Emerging, limited indications |
| Idecabtagene Vicleucel (CAR-T) |
Chimeric antigen receptor T-cell therapy targeting BCMA |
Bristol Myers Squibb |
Established in RRMM |
| Ciltacabtagene Autoleucel (CAR-T) |
Chimeric antigen receptor T-cell therapy targeting BCMA |
Janssen (J&J)/Legend |
Established in RRMM |
| Teclistamab (Bispecific) |
Bispecific antibody targeting BCMA and CD3 |
Janssen (J&J) |
Emerging in RRMM |
| Elranatamab (Bispecific) |
Bispecific antibody targeting BCMA and CD3 |
Pfizer |
Emerging in RRMM |
| GPRC5D-targeting Bispecific |
Bispecific antibody targeting GPRC5D and CD3 |
Various |
Early-stage development |
Analysis of key players and therapeutic modalities in the MM landscape.
Key Takeaways
Daratumumab continues to demonstrate clinical value and market leadership in multiple myeloma. Its expanding portfolio of indications, particularly in newly diagnosed patients and in combination regimens, underpins a projection of sustained market growth. The subcutaneous formulation has enhanced its competitive positioning. While facing competition from emerging novel therapies, daratumumab's established efficacy and safety profile ensure its continued relevance.
Frequently Asked Questions
-
What is the primary mechanism of action for daratumumab?
Daratumumab is a human IgG1 kappa monoclonal antibody that binds to the CD38 molecule expressed on the surface of multiple myeloma cells. It mediates tumor cell death through various immune effector mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis.
-
Which patient populations benefit most from daratumumab therapy currently?
Daratumumab offers significant benefit across multiple myeloma patient populations. This includes patients with newly diagnosed multiple myeloma (NDMM) receiving upfront therapy, and patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies. Its use as maintenance therapy post-treatment is also expanding.
-
What is the clinical significance of the subcutaneous formulation of daratumumab?
The subcutaneous formulation (Darzalex Faspro) offers a shorter administration time (approximately 3-5 minutes compared to up to 2 hours for the intravenous formulation), improved patient convenience, and reduced healthcare resource utilization. This has facilitated broader adoption, particularly in outpatient settings.
-
What are the main challenges facing the continued market growth of daratumumab?
Key challenges include the increasing development and market entry of alternative novel therapies like CAR T-cell therapies and bispecific antibodies that target different pathways. Additionally, evolving payer landscapes and pricing pressures in the pharmaceutical market could impact future revenue growth.
-
Are there any clinical trials investigating daratumumab beyond multiple myeloma?
Yes, daratumumab is under investigation in other hematological malignancies. Early-phase clinical trials are exploring its efficacy in conditions such as AL amyloidosis, mantle cell lymphoma, and chronic lymphocytic leukemia, where CD38 expression is relevant.
Citations
[1] Genmab. (n.d.). Daratumumab in Multiple Myeloma. Retrieved from [Genmab Website] (Specific URL not provided as it requires direct access to proprietary information or a general company website link)
[2] Janssen. (n.d.). Darzalex Prescribing Information. Retrieved from [Janssen Website] (Specific URL not provided as it requires direct access to proprietary information or a general company website link)
[3] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/
[4] Market Research Reports (e.g., Global Data, IQVIA, Evaluate Pharma). (Various Dates). Multiple Myeloma Market Analysis and Forecasts. (Specific report titles and dates are proprietary and vary).
[5] Lonial, S., et al. (2016). Daratumumab plus lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (CASTOR): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3(4), e191-e201.
[6] Palumbo, A., et al. (2018). Daratumumab, bortezomib, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet Haematology, 5(11), e547-e558.
[7] Munshi, N. C., et al. (2021). Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 39(13), 1416-1425.
